Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Novel Strategy for Treating Castration-Resistant Prostate Cancer (Volume II)
share announcement

Novel Strategy for Treating Castration-Resistant Prostate Cancer (Volume II)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 1873

Special Issue Editor

Prof. Dr. Shu-Pin Huang

E-Mail Website
Guest Editor
Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Interests: prostate cancer; uro-oncology; biomarkers; targeted therapy; precision medicine; molecular epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Prostate cancer is the most frequently diagnosed cancer among men. Androgen deprivation therapy (ADT) has emerged as a first-line therapy for initial management of advanced or metastatic prostate cancer; however, many patients eventually develop castration-resistant prostate cancer (CRPC) and distant metastasis, accounting for the majority of the mortality from the prostate cancer. Although several new options for the treatment of metastatic CRPC (mCRPC) have been approved in the last few years: the CYP17 inhibitor abiraterone, the androgen receptor (AR) antagonist enzalutamide, the taxane cabazitaxel, the immunotherapy sipuleucel-T and the alpha-emmitter radium-223 for men with bone metastases, CRPC remains incurable. To improve the therapeutic efficacy of CRPC or develop a novel therapeutic agent is urgently needed. This Special Issue of Biomedicines, entitled “Novel strategy for treating castration-resistant prostate cancer,” will include reviews that describe novel strategies for treating CRPC developed over the past few years as well as original research articles that describe novel strategies for treating CRPC using preclinical and/or translational studies. In addition, studies in combination therapy, drug response, tumor microenvironment, and mechanistic approaches will be accepted.

Prof. Dr. Shu-Pin Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • hormonal therapy
  • chemotherapy
  • immunotherapy
  • natural bioactive products
  • targeted therapies
  • biomarkers
  • precision medicine
  • tumor microenvironment
  • cancer stem cells

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 2034 KiB  
Article
Therapeutic Potential of Bipolar Androgen Therapy for Castration-Resistant Prostate Cancer: In Vitro and In Vivo Studies
by Jiwoong Yu, Joung Eun Lim and Wan Song
Biomedicines 2024, 12(1), 181; https://doi.org/10.3390/biomedicines12010181 - 15 Jan 2024
Viewed by 1038
Abstract
Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer (PCa), but resistance often leads to castration-resistant PCa (CRPC). CRPC remains androgen receptor (AR)-dependent, and AR overexpression causes vulnerability to high doses of androgen in CRPC. Bipolar androgen therapy (BAT) refers [...] Read more.
Androgen deprivation therapy (ADT) is a primary treatment for advanced prostate cancer (PCa), but resistance often leads to castration-resistant PCa (CRPC). CRPC remains androgen receptor (AR)-dependent, and AR overexpression causes vulnerability to high doses of androgen in CRPC. Bipolar androgen therapy (BAT) refers to the periodic administration of testosterone, resulting in oscillation between supraphysiologic and near-castrate serum testosterone levels. In this study, we evaluated the efficacy of BAT against CRPC in a preclinical setting. To emulate CRPC characteristics, PCa cell lines (LNCaP, VCaP, and 22Rv1) were cultured in phenol red-free RPMI-1640 medium supplemented with 10% dextran-coated charcoal treated FBS (A− cell line). Cell viability, AR, and AR-V7 expression were evaluated using the Cell Counting Kit-8 and Western blotting. In vivo studies involved 12 castrated NOG mice injected with LNCaP/A− cells, treated with testosterone pellets or controls in 2-week cycles. Tumor sizes were measured post a 6-week treatment cycle. Bicalutamide inhibited PCa cell viability but not in the adapted cell lines. Supraphysiologic androgen levels suppressed AR-expressing PCa cell growth in vitro. In vivo, high AR-expressing LNCaP cells proliferated under castrate conditions, while BAT-treated xenografts exhibited significant growth inhibition with low Ki-67 and mitotic indexes and a high cell death index. This study provides preliminary evidence that BAT is effective for the treatment of CRPC through rapid cycling between supraphysiologic and near-castrate serum testosterone levels, inducing an anti-tumor effect. Full article
(This article belongs to the Special Issue Novel Strategy for Treating Castration-Resistant Prostate Cancer (Volume II))
►▼ Show Figures

Figure 1

Other

Jump to: Research

24 pages, 4840 KiB  
Systematic Review
Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review
by Finn Edler von Eyben, Kalevi Kairemo and Daniel S. Kapp
Biomedicines 2024, 12(4), 822; https://doi.org/10.3390/biomedicines12040822 - 08 Apr 2024
Viewed by 520
Abstract
Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review [...] Read more.
Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review (SR) aimed to summarize uPSAs for patients with localized PCa. The SR was registered as InPLASY2023110084. We searched for studies on Google Scholar, PUBMED and reference lists of reviews and studies. We only included studies on uPSAs published in English and excluded studies of women, animals, sarcoidosis and reviews. Of the 115 included studies, 39 reported PSA assay methods and 76 reported clinical findings. Of 67,479 patients, 14,965 developed PSA recurrence (PSAR) and 2663 died. Extremely low PSA nadir and early developments of PSA separated PSAR-prone from non-PSAR-prone patients (cumulative p value 3.7 × 1012). RP patients with the lowest post-surgery PSA nadir and patients who had the lowest PSA at SRT had the fewest deaths. In conclusion, PSA for patients with localized PCa in the pre-PSAR phase of PCa is strongly associated with later PSAR and survival. A rising but still exceedingly low PSA at SRT predicts a good 5-year overall survival. Full article
(This article belongs to the Special Issue Novel Strategy for Treating Castration-Resistant Prostate Cancer (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop